When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement on aducanumab.)

The Centers for Medicare and Medicaid Services (CMS) has proposed limiting coverage of drugs in this new class, at least for now, to only participants of clinical trials.

Since a third of people with dementia with Lewy bodies also have co-existing Alzheimer’s disease, LBDA spoke out on behalf of the LBD community. Read what we had to say at LBDA.org.